Skip to main content
VALN
NASDAQ Life Sciences

Valneva & Pfizer Announce Positive Phase 3 Results for Lyme Vaccine; Regulatory Submissions Planned

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.51
Mkt Cap
$907.452M
52W Low
$5.429
52W High
$12.25
52W Position info
20% above low
Off High info
47% below high
Rel. Volume info
25× avg
Market data snapshot near publication time

VALN sits 20% above its 52-week low of $5.429 on elevated volume (25× avg).

Summary

Valneva and Pfizer announced positive topline Phase 3 results for their Lyme disease vaccine candidate, PF-07307405, demonstrating over 70% efficacy and a good safety profile. Despite a technical miss on the primary statistical criterion, Pfizer plans to proceed with regulatory submissions.


Key Events · Product Development and Regulatory · VALN

  • Positive Phase 3 Topline Results

    The investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and above.

  • Favorable Safety Profile

    No safety concerns were identified during the analysis of the Phase 3 VALOR clinical trial.

  • Regulatory Submissions Planned

    Despite a technical miss on the primary statistical criterion, Pfizer is confident in the vaccine's potential due to clinically meaningful efficacy and plans to proceed with regulatory submissions.


Analysis · VALN · Life Sciences

This filing provides crucial positive news for Valneva, offering a significant counter-balance to recent negative disclosures, including an adverse audit opinion, lower financial guidance, and an FDA manufacturing facility issue. The successful Phase 3 trial for the Lyme disease vaccine candidate, developed in partnership with Pfizer, significantly de-risks a key pipeline asset. While the primary endpoint's statistical criterion was not met, the clinically meaningful efficacy of over 70% and Pfizer's commitment to regulatory submissions are strong indicators of the vaccine's potential. Investors will now watch for the timing of regulatory filings and subsequent approvals, which could provide a substantial revenue stream for Valneva through its collaboration with Pfizer.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VALN was trading at $6.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $907.5M. The 52-week trading range was $5.43 to $12.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VALN - Latest Insights

VALN
Nov 13, 2026, 10:09 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.84
Real-time Price: $5.17 info
Change: -$0.675 (-12%) info
Market Cap: $511.074M info
VALN
Nov 09, 2026, 10:37 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $5.79
Real-time Price: $5.17 info
Change: -$0.625 (-11%) info
Market Cap: $511.074M info
VALN
Oct 07, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $5.17 info
Change: -$0.445 (-8%) info
Market Cap: $511.074M info
VALN
Aug 14, 2026, 11:27 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $7.01
Real-time Price: $5.17 info
Change: -$1.84 (-26%) info
Market Cap: $511.074M info
VALN
Aug 13, 2026, 10:27 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.45
Real-time Price: $5.17 info
Change: -$0.285 (-5%) info
Market Cap: $511.074M info